例如在文旅赛道，复星多个产品线取得新年开门红。Club Med国内五家精致"一价全包"度假村春节核心 假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增长20%。 "复星选择在本次年度报表中一次性计提大额的非现金账面亏损，实为主动出清风险，继续推进其'瘦身 健体、聚焦主业'战略。"上述分析人士表示，抛下包袱之后，复星未来增长逻辑更加清晰。 【复星国际：地产、商誉减值计提致账面亏损 不影响整体运营和现金流】《中国经营报》记者了解 到，日前复星国际（00656.HK）发布盈利预警公告称，根据现有资料及截至2025年12月31日最新未经 审核综合管理账目，2025财政年度归属于母公司股东之亏损预计约为人民币215亿元至人民币235亿元。 亏损主要由于对部分资产进行了一次性的非现金减值计提和价值重估，不影响公司整体运营和现金流。 公告同时强调，公司基本面保持稳健，将持续推进"聚焦主业"的企业战略和"瘦身健体"的财务战略，通 过精细化运营促进业务增长，夯实长期价值。 复星国际在公告中陈述了年度大额账面亏损的主要原因。一是2025财政年度内，房地产行业下行周期持 续，市场整体需求疲软 ...

Market Overview - The Hang Seng Index decreased by 0.24%, closing at 25,898.76 points, with a total market turnover of 254.48 billion HKD [1]. Southbound Trading Activity - The net buying amounts for southbound funds included: - China National Offshore Oil Corporation (CNOOC) with a net buy of 1.039 billion HKD - Alibaba Group Holding Limited (Alibaba-W) with a net buy of 698 million HKD - Geely Automobile Holdings Limited with a net buy of 532 million HKD [1][2]. - The net selling amounts for southbound funds included: - Tencent Holdings Limited with a net sell of 2.435 billion HKD - China Construction Bank with a net sell of 826 million HKD - Industrial and Commercial Bank of China with a net sell of 185 million HKD [1][2]. Individual Stock Performance - CNOOC's stock price increased by 3.70% to 28.06 HKD [2]. - Geely Automobile's stock price rose by 8.21% to 17.39 HKD [2]. - Alibaba's stock price slightly decreased by 0.22% to 133.20 HKD [2]. - Tencent's stock price fell by 0.27% to 552.00 HKD [2]. - China Construction Bank's stock price decreased by 0.96% to 6.22 HKD [2]. - Industrial and Commercial Bank of China's stock price dropped by 1.64% to 7.78 HKD [2].

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Chengdu Tianqing Pharmaceutical, has received clinical trial approval from the NMPA for its innovative drug TQB3205, a pan-KRAS inhibitor aimed at treating advanced malignant tumors [1][2] Group 1: Product Development - TQB3205 is an oral pan-KRAS inhibitor that binds with high affinity to various KRAS mutant proteins, inhibiting SOS1-mediated nucleotide exchange and blocking RAS activation, thereby effectively suppressing the proliferation of various KRAS mutant tumor cells [1] - The KRAS gene is the most frequently mutated gene in the RAS family, with approximately 30% of cancer cases associated with RAS gene mutations, and KRAS mutations account for 85% of all RAS mutations, prevalent in pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%) [1] - Currently, five KRAS inhibitors approved globally only target the G12C mutation subtype, highlighting the need for broader coverage of KRAS mutation subtypes [1][2] Group 2: Market Demand and Strategy - The clinical demand in the KRAS field remains unmet, necessitating the development of pan-KRAS inhibitors that can address a wider range of mutation subtypes [2] - The company aims to accelerate the clinical development of TQB3205 to provide new treatment options for patients with advanced malignant tumors harboring various KRAS mutations [2]

宝胜国际(03813.HK)发布公告，该公司将于2026年6月23日派发末期股息每股0.002港元。 截至2026年3月11日收盘，宝胜国际(03813.HK)报收于0.45港元，上涨3.45%，成交量262.7万股，成交额 116.52万港元。投行对该股关注度不高，90天内无投行对其给出评级。 宝胜国际港股市值23.17亿港元，在专业零售行业中排名第6。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

KRAS基因是RAS家族中突变频率最高的基因。全球约30%的癌症病例与RAS基因突变相关，其中由 KRAS突变导致的癌症占所有RAS突变的85%，在胰腺癌(90%)、结直肠癌(30%-50%)、非小细胞肺癌( 15%-20%)等多种癌症中普遍存在。然而，不同肿瘤类型的KRAS突变亚型差异显着，常见类型包括 G12C、G12V、G12D、G13D等。目前全球已获批上市的5款KRAS抑制剂均仅针对G12C单一突变亚 型。 本集团联合开发的KRAS G12C抑制剂格索雷塞(商品名：安方宁)已于2024年11月获得NMPA的上市批 准。尽管如此，KRAS领域的临床需求远未得到满足，亟需能覆盖更广泛突变亚型的pan-KRAS抑制 剂。本集团将加速推动TQB3205的临床开发，致力于突破现有治疗局限，为更广泛的KRAS突变晚期恶 性肿瘤患者带来新的治疗选择。 智通财经APP讯，中国生物制药(01177)发布公告，本集团附属公司正大天晴药业集团股份有限公司(正 大天晴)自主研发的国家1类创新药TQB3205(pan-KRAS 抑制剂)已获得中国国家药品监督管理局(NMPA) 的临床试验批准，拟用于治疗晚期恶性肿瘤。 TQB ...

智通财经APP获悉，香港联交所最新资料显示，3月10日，MGD Holdings减持中海石油化学(03983)523 万股，每股均价3.102港元，总金额约为1622.35万港元。减持后最新持股数目约为1.96亿股，最新持股 比例10.94%。 ...

香港联交所最新资料显示，3月10日，MGD Holdings减持中海石油化学(03983)523万股，每股均价3.102 港元，总金额约为1622.35万港元。减持后最新持股数目约为1.96亿股，最新持股比例10.94%。 ...

格隆汇3月11日丨中国生物制药(01177.HK)宣布，集团附属公司正大天晴药业集团股份有限公司(「正大 天晴」)自主研发的国家1类创新药TQB3205「pan-KRAS抑制剂」已获得中国国家药品监督管理局 (NMPA)的临床试验批准，拟用于治疗晚期恶性肿瘤。 KRAS基因是RAS家族中突变频率最高的基因。全球约30%的癌症病例与RAS基因突变相关，其中由 KRAS突变导致的癌症占所有RAS突变的85%，在胰腺癌(90%)、结直肠癌(30%-50%)、非小细胞肺癌 (15%-20%)等多种癌症中普遍存在[1-2]。然而，不同肿瘤类型的KRAS突变亚型差异显着，常见类型包 括G12C、G12V、G12D、G13D等[3-4]。目前全球已获批上市的5款KRAS抑制剂均仅针对G12C单一突 变亚型。 集团联合开发的KRASG12C抑制剂格索雷塞(商品名：安方宁)已于2024年11月获得NMPA的上市批准。 尽管如此，KRAS领域的临床需求远未得到满足，亟需能覆盖更广泛突变亚型的pan-KRAS抑制剂。集 团将加速推动TQB3205的临床开发，致力于突破现有治疗局限，为更广泛的KRAS突变晚期恶性肿瘤患 者带来新的治 ...

资本市场高度关注吉利汽车的高端化进展。据悉，极氪8X将于3月16日晚举办技术发布会，该车首发搭 载最新版千里浩瀚G-ASD高阶辅助驾驶系统，以及全球混动领域首个全栈900V高压动力系统，满油满 电综合续航突破1000公里，并支持6C超充技术，被业内视为有望接棒极氪9X的又一款高端爆款车型。 更详尽的高端化战略布局及2025年度财务表现，将于3月18日召开的吉利汽车年度业绩发布会上正式披 露。 本报讯 （记者刘钊）3月11日，吉利汽车控股有限公司（以下简称"吉利汽车"，0175.HK）盘中表现强 劲，股价大幅拉升，一度涨近10%，跑赢港股大盘及一众汽车股，股价创今年历史新高。截至当日收 盘，吉利汽车报17.39港元，涨8.21%。 ...

Core Viewpoint - The article highlights that the Iranian Tasnim News Agency has identified U.S. companies with ties to Israel as new targets, indicating an escalation in regional conflict that now includes infrastructure warfare [1] Group 1: Companies Listed - The companies mentioned include Google, Microsoft, Palantir, IBM, Nvidia, and Oracle, all of which have operations in Israel and the Gulf region [1] - These companies' technologies have been utilized for military purposes, making their offices and cloud-based facilities potential targets in the ongoing conflict [1] Group 2: Context of the Conflict - The report indicates that as U.S. tech companies rapidly expand their data center networks in the Middle East, the significant investments in regional AI infrastructure are now being recognized as targets in the battlefield [1]